Preclinical toxicology, pharmacology, and efficacy of a novel orally administered diethylenetriaminepentaacetic acid (DTPA) formulation

Drug Development Research

Volumn 73, Issue 5, 2012, Pages 232-242

  Reddy, Joseph D ^a   Cobb, Ronald R ^a   Dungan, Nathanael W ^a   Matthews, Laura L ^a   Aiello, Kenneth V ^a   Ritter, Gregg ^a   Kirk, James F ^a   Abernethy, John A ^a   Tomisaka, Dennis M ^a   Talton, James D ^a  

^a NANO ADM Advanced Development and Manufacturing Center   (United States)

Author keywords

decorporation; DTPA; radiation; toxicology; zinc

Indexed keywords

AMERICIUM 241; GELATIN; NANODTPA; PENTETATE ZINC; PENTETIC ACID; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHELATION THERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TISSUE LEVEL; ENTERIC COATED CAPSULE; EXPERIMENTAL DOG; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; NANOPHARMACEUTICS; NONHUMAN; RADIOACTIVITY; RAT; SUSTAINED RELEASE PREPARATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84865097261     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21018     Document Type: Article

References (30)

1. Abergel RJ, Durbin PW, Kullgren B, Ebbe SN, Xu J, Chang PY, Bunin DI, Blakely EA, Bjornstad KA, Rosen CJ, et al. 2010. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Phys 99: 401-407.
2. Bruenger FW, Kuswik-Rabiega G, Miller SC,. 1992. Decorporation of aged americium deposits by oral administration of lipophilic polyamino carboxylic acids. J Med Chem 35: 112-118.
3. Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW,. 2008. Medical countermeasures against nuclear threats: radionuclide decorporation agents. Radiat Res 170: 540-548.
4. Durbin PW,. 2008. Lauriston S. Taylor lecture: the quest for therapeutic actinide chelators. Health Phys 95: 465-492.
5. Durbin PW, Kullgren B, Ebbe SN, Xu J, Raymond KN,. 2000. Chelating agents for uranium(VI): 2. Efficacy and toxicity of tetradentate catecholate and hydroxypyridinonate ligands in mice. Health Phys 78: 511-521. (Pubitemid 30210786)
6. Durbin PW, Kullgren B, Xu J, Raymond KN, Henge-Napoli MH, Bailly T, Burgada R,. 2003. Octadentate hydroxypyridinonate (HOPO) ligands for plutonium (i.v.): pharmacokinetics and oral efficacy. Radiat Prot Dosimetry 105: 503-508. (Pubitemid 37161281)
7. Food and Drug Administration (FDA). 2002. Food and Drug Administration (FDA) Guidance for industry on pentetate calcium trisodium and pentetate zinc trisodium for treatment of internal contamination with plutonium, americium or curium; availability. Fed Regist 68: 53984-53988.
8. Gorden AE, Xu J, Raymond KN, Durbin P,. 2003. Rational design of sequestering agents for plutonium and other actinides. Chem Rev 103: 4207-4282.
9. Grace MB, Moyer BR, Prasher J, Cliffer KD, Ramakrishnan N, Kaminski J, Coleman CN, Manning RG, Maidment BW, Hatchett R,. 2010. Rapid radiation dose assessment for radiological public health emergencies: roles of NIAID and BARDA. Health Phys 98: 172-178.
10. Gray SA, Pearce MJ, Stradling GN, Wilson I, Hodgson A, Isaacs KR,. 1995. Optimising the removal of inhaled plutonium and americium from the rat by administration of ZnDTPA in drinking water. Hum Exp Toxicol 14: 902-908.
11. James AC, Sasser LB, Stuit DB, Glover SE, Carbaugh EH,. 2007. Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu. Radiat Prot Dosimetry 127: 449-455.
12. Kety S,. 1942. The lead citrate complex ion and its role in the physiology and therapy of lead poisoning. J Biol Chem 14: 181-192.
13. Kostial K, Kargacin B, Landeka M,. 1987a. Oral Zn-DTPA therapy for reducing 141Ce retention in suckling rats. Int J Radiat Biol Relat Stud Phys Chem Med 52: 501-504. (Pubitemid 17153763)
14. Kostial K, Kargacin B, Landeka M,. 1987b. Oral Zn-DTPA treatment reduces cadmium absorption and retention in rats. Toxicol Lett 39: 71-75. (Pubitemid 17157065)
15. Miller SC, Bruenger FW, Kuswik-Rabiega G, Liu G, Lloyd RD,. 1993. Duration and dose-related effects of an orally administered, partially lipophilic polyaminocarboxylic acid on the decorporation of plutonium and americium. J Pharmacol Exp Ther 267: 548-554. (Pubitemid 23325050)
16. Miller SC, Bruenger FW, Kuswik-Rabiega G, Lloyd RD,. 1992. Decorporation of plutonium by oral administration of a partially lipophilic polyaminocarboxylic acid. Health Phys 63: 195-197.
17. Miller SC, Liu G, Bruenger FW, Lloyd RD,. 2006. Efficacy of orally administered amphipathic polyaminocarboxylic acid chelators for the removal of plutonium and americium: comparison with injected Zn-DTPA in the rat. Radiat Prot Dosimetry 118: 412-420. (Pubitemid 44313431)
18. Miller SC, Wang X, Bowman BM,. 2010. Pharmacological properties of orally available, amphipathic polyaminocarboxylic acid chelators for actinide decorporation. Health Phys 99: 408-412.
19. Paquet F, Chazel V, Houpert P, Guilmette R, Muggenburg B,. 2003. Efficacy of 3,4,3-LI(1,2-HOPO) for decorporation of Pu, Am and U from rats injected intramuscularly with high-fired particles of MOX. Radiat Prot Dosimetry 105: 521-525. (Pubitemid 37161285)
20. Pellmar TC, Rockwell S,. 2005. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 163: 115-123. (Pubitemid 40039952)
21. Seidel A, Kruger E, Wiener M, Hotz G, Balani M, Thies WG,. 1985. Association of 239Pu with lysosomes in rat, Syrian hamster, and Chinese hamster liver as studied by carrier-free electrophoresis and electron microscopic autoradiography with 241Pu. Radiat Res 104 (2 Pt 1): 191-199. (Pubitemid 16174848)
22. Stradling GN, Gray SA, Ellender M, Pearce M, Wilson I, Moody JC, Hodgson A,. 1993. Removal of inhaled plutonium and americium from the rat by administration of ZnDTPA in drinking water. Hum Exp Toxicol 12: 233-239. (Pubitemid 23162531)
23. Taylor DM,. 1989. The biodistribution and toxicity of plutonium, americium and neptunium. Sci Total Environ 83: 217-225. (Pubitemid 19178032)
24. Taylor DM, Hodgson SA, Stradling N,. 2007. Treatment of human contamination with plutonium and americium: would orally administered Ca- or Zn-DTPA be effective? Radiat Prot Dosimetry 127: 469-471.
25. Taylor DM, Lehmann M, Planas-Bohne F, Seidel A,. 1983. The metabolism of radiohafnium in rats and hamsters: a possible analog of plutonium for metabolic studies. Radiat Res 95: 339-358. (Pubitemid 13020925)
26. Taylor DM, Volf V,. 1980. Oral chelation treatment of injected 241Am or 239Pu in rats. Health Phys 38: 147-158. (Pubitemid 10111958)
27. Volf V, Luz A, Schaffer E, Muller WA, Rencova J,. 1999. Effect of oral ZnDTPA on late effects of injected plutonium in rat. Int J Radiat Biol 75: 929-941. (Pubitemid 29372051)
28. Wirth R, Taylor DM, Duffield J,. 1985. Identification of transferrin as the principal neptunium-binding protein in the blood serum of rats. Int J Nucl Med Biol 12: 327-330. (Pubitemid 16232481)
29. Xu J, Durbin PW, Kullgren B, Ebbe SN, Uhlir LC, Raymond KN,. 2002. Synthesis and initial evaluation for in vivo chelation of Pu(IV) of a mixed octadentate spermine-based ligand containing 4-carbamoyl-3-hydroxy-1-methyl- 2(1H)-pyridinone and 6-carbamoyl-1-hydroxy-2(1H)-pyridinone. J Med Chem 45: 3963-3971. (Pubitemid 35024298)
30. Xu J, Kullgren B, Durbin PW, Raymond KN,. 1995. Specific sequestering agents for the actinides. 28. Synthesis and initial evaluation of multidentate 4-carbamoyl-3-hydroxyl-1-methyl-2(1H)-pyridinone ligands for in vivo plutonium(IV) chelation. J Med Chem 38: 2606-2614.